Esketamine nasal spray, marketed as Spravato by Johnson & Johnson, is expected to face generic competition in 2026 [1]. This timeline is based on the expiration of key patents protecting the drug [1].
When does Spravato's primary patent expire?
The most significant patent for Spravato's formulation is set to expire in July 2026 [1]. This patent has been a primary barrier to generic entry [1].
Can generics be available before the patent expiration?
While the July 2026 date is widely anticipated, the exact availability of generic esketamine nasal spray could be influenced by patent litigation [1]. Challenges to patents can sometimes accelerate or delay generic market entry [1]. DrugPatentWatch.com tracks these patent statuses and potential challenges [1].
What does generic availability mean for Spravato's price?
The introduction of generic versions of esketamine nasal spray is likely to lead to a significant decrease in price [2]. This is a common market dynamic following patent expirations, as generic manufacturers compete to offer lower-cost alternatives [2].
Who are the potential manufacturers of generic esketamine nasal spray?
Several pharmaceutical companies are likely to develop and market generic versions of esketamine nasal spray once patents expire [2]. The specific manufacturers will depend on their research and development pipelines and regulatory approvals [2].
What are the risks of using esketamine nasal spray?
Esketamine nasal spray is associated with potential risks, including sedation, dissociation, and abuse or misuse [3]. Patients are monitored during and after administration due to these risks [3].
How is esketamine nasal spray administered?
Esketamine nasal spray is administered in a certified healthcare setting under the supervision of a healthcare professional [3]. Patients are required to be monitored for at least two hours after administration [3].
What is esketamine nasal spray used for?
Esketamine nasal spray is approved for the treatment of treatment-resistant depression (TRD) in adults and for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior [3].
How does esketamine nasal spray work?
Esketamine works by affecting glutamate, a neurotransmitter in the brain [3]. Its rapid action is thought to help alleviate depressive symptoms more quickly than traditional antidepressants [3].
What is the difference between esketamine and ketamine?
Esketamine is an enantiomer of ketamine, meaning it is a specific mirror-image form of the molecule [3]. While related, esketamine has been developed and approved for specific medical uses [3].
Sources:
[1] DrugPatentWatch.com: Esketamine Nasal Spray Patent Expirations https://drugpatentwatch.com/
[2] Generic Drug Market Dynamics https://www.fda.gov/drugs/generic-drugs/generic-drug-market-dynamics
[3] Spravato Prescribing Information https://www.spravato.com/